Statistics

Total Visits

Views
Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)75

Select a period of time:

Number of views in the range

Views
Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)15

Views

Views
June 20250
July 20259
August 20250
September 20252
October 20250
November 20253
December 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
Brazil4
Argentina1
Canada1
Ecuador1
Morocco1
Venezuela1
 

Top cities views

Views
Dallas2
Atibaia1
Barinas1
Brantford1
Daule1
Hendersonville1
Hinsdale1
Houston1
Lomas de Zamora1
Meknes1